AstraZeneca $1.2bn collaboration expands metabolic footprint
AstraZeneca has significantly expanded its footprint in the metabolic disease market by entering into a strategic collaboration with Hong Kong-based CSPC Pharmaceutical Group. The landmark agreement, announced on January 30, focuses on the development of eight next-generation programs for obesity and type 2 diabetes, leveraging CSPC’s advanced AI-driven peptide discovery platform and proprietary LiquidGel monthly dosing technology. Under the financial…
Optimed bought by listed Hong Kong company
Optimed Medizinische Instrumente, the Germany-based specialist in minimally invasive therapy devices, is being bought by Hong Kong listed medical technology firm Zylox-Tonbridge. The acquisition signals a major shift as the acquirer transitions into a truly multinational medical technology entity with a strengthened presence in Europe. The definitive agreement to acquire, announced on January 16, marks a defining milestone in the…